MedTrace Logo

Tyrosine Allergoid Paediatric and Adult Study

NCT05186025 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 320

Last updated 2026-01-30

No results posted yet for this study

Summary

The primary objective of this 5-year study is to demonstrate non-inferiority of children compared to adults by exploring long-term effectiveness after treatment with TA Bäume (trees) and TA Gräser (grass) following a perennial posology.

Conditions

  • Allergic Rhinitis Due to Pollen
  • Allergic Conjunctivitis
  • Allergic Asthma

Interventions

DRUG

MATA trees or MATA grass

Glutaraldehyde-modified and MCT® (MicroCrystalline Tyrosine)-adsorbed allergoids

Sponsors & Collaborators

  • Bencard Allergie GmbH

    collaborator OTHER

  • Allergy Therapeutics

    lead INDUSTRY

Principal Investigators

  • Ralph Moesges, Prof. · ClinCompetence Cologne GmbH

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-06
Primary Completion
2026-06-30
Completion
2026-10-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05186025 on ClinicalTrials.gov